Why Lantheus Holdings Stock Got Thrashed on Tuesday
Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...
GlobalData on MSN2d
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn
The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.
Lantheus is on a buying spree. Its latest deal is worth up to $1B
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
Outsourcing-pharma1d
Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline
Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
FiercePharma3d
Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen
On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...
MM&M3d
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront
Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...
Lantheus’s Strategic Acquisition of Evergreen Theragnostics Strengthens Radiopharmaceutical Leadership and Growth Prospects
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence: ...
Lantheus appoints Morrow as new board member
Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus’ Board of Directors, effective February 1, 2025. As an ...
Lantheus expands in neuro and oncology with LMI and Evergreen acquisitions
Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and ...
Contract Pharma3d
Lantheus Holdings to Acquire Evergreen Theragnostics
Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...
Hosted on MSN3d
Lantheus to Acquire Evergreen Theragnostics for $250 Million
Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an ...